How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Sickle Cell Disease Therapeutics Market
- By Therapeutic Class: Hydroxyurea, L-glutamine, Voxelotor, Crizanlizumab, Gene Therapy
- By Treatment Modality: Pharmacological Treatment, Gene Editing Therapy, Bone Marrow Transplantation, Supportive Care
- By Patient Age Group: Pediatric, Adult, Geriatric
- By Disease Severity: Mild Sickle Cell Disease, Moderate Sickle Cell Disease, Severe Sickle Cell Disease
- By Mechanism of Action: Hemoglobin Modulators, Anti-adhesion Agents, Antioxidants, Gene Modification Agents
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hydroxyurea leads By Therapeutic Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Sickle Cell Disease Therapeutics Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Class 5
Treatment Modality 4
Patient Age Group 3
Disease Severity 3
Mechanism of Action 4
Companies profiled
Novartis AG
Bluebird Bio Inc.
Global Blood Therapeutics Inc.
Pfizer Inc.
Sanofi S.A.
Vertex Pharmaceuticals Incorporated
Addmedica
Novo Nordisk A/S
Gilead Sciences Inc.
Bristol-Myers Squibb Company
Amgen Inc.
Sangamo Therapeutics Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bluebird Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Global Blood Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Vertex Pharmaceuticals Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Addmedica
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Novo Nordisk A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Gilead Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sangamo Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →CRISPR Therapeutics AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Editas Medicine Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Orchard Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,464M by 2033 · 7.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hydroxyurea38.4
- L-glutamine13.1
- Voxelotor14.0
- Crizanlizumab16.9
- Gene Therapy17.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$845.7M → $1,644M · 8.7%
Europe$589.5M → $913.8M · 5.6%
Asia Pacific$538.2M → $910.5M · 6.8%
Latin America$333.2M → $539.4M · 6.2%
Middle East and Africa$256.3M → $435.4M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.132026
7.152027
7.162028
7.172029
7.182030
7.202031
7.212032
7.222033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG15.8
- Bluebird Bio Inc.13.0
- Global Blood Therapeutics Inc.10.6
- Pfizer Inc.11.3
- Sanofi S.A.11.4
- Vertex Pharmaceuticals Incorporated10.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Class11.4%
Treatment Modality20.9%
Patient Age Group18.0%
Disease Severity29.4%
Mechanism of Action20.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America37.0
- Europe20.6
- Asia Pacific20.5
- Latin America12.1
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 91 | 82 | 86 | 79 | 76 | 91 | 84 |
| Bluebird Bio Inc. | 73 | 69 | 85 | 82 | 83 | 84 | 79 |
| Global Blood Therapeutics Inc. | 71 | 77 | 68 | 65 | 82 | 77 | 73 |
| Pfizer Inc. | 70 | 81 | 79 | 71 | 70 | 58 | 72 |
| Sanofi S.A. | 65 | 72 | 63 | 60 | 53 | 54 | 61 |
| Vertex Pharmaceuticals Incorporated | 46 | 69 | 61 | 55 | 56 | 48 | 56 |
| Addmedica | 44 | 61 | 51 | 57 | 54 | 56 | 54 |
| Novo Nordisk A/S | 40 | 40 | 35 | 58 | 54 | 49 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Bluebird Bio Inc.
- Global Blood Therapeutics Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Bluebird Bio Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Global Blood Therapeutics Inc. | ◐ | ◐ | − | − | ✓ | ✓ |
| Pfizer Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | − |
| Sanofi S.A. | ◐ | ◐ | ◐ | − | − | ◐ |
| Vertex Pharmaceuticals Incorporated | − | − | ✓ | ◐ | ◐ | ◐ |
| Addmedica | − | ◐ | ◐ | ◐ | − | − |
| Novo Nordisk A/S | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG84
2Bluebird Bio Inc.79
3Global Blood Therapeutics Inc.73
4Pfizer Inc.72
5Sanofi S.A.61
6Vertex Pharmaceuticals Incorporated56
7Addmedica54
8Novo Nordisk A/S46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGBluebird Bio Inc.
Challenger2
Strong scale, closing on the leaders.
Global Blood Therapeutics Inc.Pfizer Inc.
Contender1
Focused players with pockets of strength.
Sanofi S.A.
Niche3
Specialists in a single segment or region.
Vertex Pharmaceuticals IncorporatedAddmedicaNovo Nordisk A/S
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Class in North America, then scale across Sickle Cell Disease Therapeutics Market — a $235M beachhead inside a $4.37B market.
Beachhead (SOM)$235Mobtainable near-term
Serviceable (SAM)$1.59Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Hydroxyurea
Best fit — highest urgency & budget in Therapeutic Class.
Economic buyer78 fit
L-glutamine
Strong fit — clear ROI and a fast path to value.
End user70 fit
Voxelotor
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel29%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Sickle Cell Disease Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation12%
Closed-won7%
$15.0KCAC
$90KLTV
6.0:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Sickle Cell Disease Therapeutics Market is a durable-growth opportunity — $9.26B by 2033, compounding at 8.1%.
TAM · 2025$4.98Btoday
TAM · 2033$9.26Bforecast
CAGR8.1%2027–2033
Cumulative$62.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.26BTotal addressable market
SAM$3.54BServiceable available market
SOM$680MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.1% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.26BLarge & growingTAM by 2033 at 8.1% CAGR
$3.54BServiceable nowreachable with today’s model
$680MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.22BBear5.2% CAGR
$9.26BBase8.1% CAGR
$11.9BBull10.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Sickle Cell Disease Therapeutics Market — a $6.15B market by 2033. Plan: grow share from 6.6% to 13.5%.
Market size · 2033$6.15Btotal addressable
Market CAGR7.7%2027–2033
Target share13.5%from 6.6% today
Revenue ambition$830Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.6% | 13.5% | On track |
| Revenue | $419M | $830M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.4% | 42.5% | On track |
| Customer retention | 84.3% | 94.1% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $115M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Sickle Cell Disease Therapeutics Market conversation — a $1.55B market you can size, segment and defend in minutes.
Market size · 2033$1.55Btotal opportunity
Growth11.2%CAGR to 2033
Addressable buyers1,636+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Class
Goal Grow share in Therapeutic Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 3 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Novartis AGBluebird Bio Inc.Global Blood Therapeutics Inc.Pfizer Inc.Sanofi S.A.Vertex Pharmaceuticals IncorporatedAddmedicaNovo Nordisk A/S+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Sickle Cell Disease Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Sickle Cell Disease Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Retinal Disorders Treatment Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportRetinal Drugs and Biologics Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportRemicade Biosimilar Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportTemporary Artificial Skin Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportPolymerase Chain Reaction (PCR) Products Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportPolymerase Chain Reaction (PCR) Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportPenile Cancer Drug Market
Market size, share, segmentation and regional forecast.
$487M market · 2025 base year
View reportPatients Handling Equipment Market
Market size, share, segmentation and regional forecast.
$731M market · 2025 base year
View reportPathology Imaging Systems Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportOphthalmic Viscosurgical Devices Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportNoninvasive Surgical Wound Closure Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportNeuroblastoma Treatment Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.